QuickView for Oxprenolol (compound)

Summary
General Info

PubChem

PubChem Compound 168869

Name:	Oxprenolol
PubChem Compound ID:	168869
Description:	A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
Molecular formula:	C₁₅H₂₄ClNO₃
Molecular weight:	301.809 g/mol
Synonyms:	(-)-1-(o-Allyloxyphenoxy)-3-isopropylamino-2-propanol hydrochloride; Ciba 42244Ba; EINECS 249-507-0; 29208-41-1; 2-Propanol, 1-(o-allyloxyphenoxy)-3-isopropylamino-, (-)-, hydrochloride; (R)-(3-(2-(Allyloxy)phenoxy)-2-hydroxypropyl)isopropylammonium chloride

DrugBank

Identification

Name:	Oxprenolol
Name (isomeric):	DB01580
Drug Type:	small molecule
Description:	A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
Synonyms:	(+)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; Osprenololo [dcit]; DL-oxprenolol; (1)-1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)propan-2-ol; (+-)-oxprenolol; 1-(Isopropylamino)-2-hydroxy-3-(o-(allyloxy)phenoxy)propane; 1-(o-(Allyloxy)phenoxy)-3-(isopropylamino)-2-propanol; Oxprenololum [inn-latin]; 1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)-2-propanol
Brand:	Slow-pren, Coretal, Laracor, Trasicor, Trasacor
Category:	Vasodilator Agents, Sympatholytics, Anti-anxiety Agents, Adrenergic beta-Antagonists, Anti-Arrhythmia Agents, Antihypertensive Agents
CAS number:	6452-71-7

Pharmacology

Indication:	Used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
Pharmacology:	Oxprenolol is a non-selective beta blocker with some intrinsic sympathomimetic activity. Oxprenolol is a lipophilic beta blocker which passes the blood-brain barrier more easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadol... show more » Oxprenolol is a non-selective beta blocker with some intrinsic sympathomimetic activity. Oxprenolol is a lipophilic beta blocker which passes the blood-brain barrier more easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadolol. Oxprenolol is an potent beta-blocker and should not be administered to asthmatics because it can cause irreversible airway failure and inflammation. show less «
Mechanism of Action:	Like other beta-adrenergic antagonists, oxprenolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, oxprenolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinep... show more » Like other beta-adrenergic antagonists, oxprenolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, oxprenolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, oxprenolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Oxprenolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. show less «
Absorption:	Oral bioavailability is 20-70%.
Biotransformation:	Hepatic.
Half Life:	1-2 hours
Toxicity:	Symptoms of overdose include abdominal irritation, central nervous system depression, coma, extremely slow heartbeat, heart failure, lethargy, low blood pressure, and wheezing.
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Avoid alcohol.

Take without regard to meals.

Avoid natural licorice.

Drug interaction:

Ibuprofen	Risk of inhibition of renal prostaglandins
Methyldopa	Possible hypertensive crisis
Ergonovine	Ischemia with risk of gangrene
Ergotamine	Ischemia with risk of gangrene
Epinephrine	Hypertension, then bradycardia

Ibuprofen	Risk of inhibition of renal prostaglandins
Methyldopa	Possible hypertensive crisis
Ergonovine	Ischemia with risk of gangrene
Ergotamine	Ischemia with risk of gangrene
Epinephrine	Hypertension, then bradycardia
Glisoxepide	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Terazosin	Increased risk of hypotension. Initiate concomitant therapy cautiously.
Clonidine	Increased hypertension when clonidine stopped
Acetohexamide	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Disopyramide	The beta-blocker, oxprenolol, may increase the toxicity of disopyramide.
Salmeterol	Antagonism
Glycodiazine	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Lidocaine	The beta-blocker increases the effect and toxicity of lidocaine
Tolbutamide	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Terbutaline	Antagonism
Glipizide	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Repaglinide	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Insulin Glargine	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Methysergide	Ischemia with risk of gangrene
Treprostinil	Additive hypotensive effect. Monitor antihypertensive therapy during concomitant use.
Salbutamol	Antagonism
Fenoterol	Antagonism
Pipobroman	Antagonism
Chlorpropamide	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Orciprenaline	Antagonism
Formoterol	Antagonism
Dihydroergotamine	Ischemia with risk of gangrene
Dihydroergotoxine	Ischemia with risk of gangrene
Isoproterenol	Antagonism
Verapamil	Increased effect of both drugs
Tolazamide	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Pirbuterol	Antagonism
Prazosin	Risk of hypotension at the beginning of therapy
Glyburide	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Insulin	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Gliclazide	The beta-blocker, oxprenolol, may decrease symptoms of hypoglycemia.
Practolol	Antagonism
Piroxicam	Risk of inhibition of renal prostaglandins
Indomethacin	Risk of inhibition of renal prostaglandins

show less «

Targets

Beta-1 adrenergic receptor

Beta-2 adrenergic receptor

Enzymes

Cytochrome P450 2D6

Transporters

Solute carrier family 22 member 2